A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.
Sutter Health has implemented a review board system to more efficiently process referrals for anti-amyloid therapies that slow Alzheimer's disease progression, as demand for these treatments increases. The approach aims to streamline access to these disease-modifying treatments for eligible patients.
A large-scale multi-ancestry genetic study led by Ole Andreassen at University of Oslo has identified new DNA risk factors for Alzheimer's disease, implicating microglial and neuronal dysregulation. The research reveals a larger common-variant contribution to the disease than previously estimated and identifies potential new drug targets.
Arrowhead Pharmaceuticals reported interim Phase 1/2a results showing its experimental RNA interference drug ARO-MAPT successfully crossed the blood-brain barrier and reduced levels of tau protein, a key marker implicated in Alzheimer's disease. The subcutaneously administered treatment represents the first RNAi medicine to achieve this effect in the brain, with analysts describing the magnitude of tau reduction as compelling and potentially superior to other blood-brain barrier platforms.
UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.
The U.S. FDA has approved AQNEURSA (levacetylleucine) as the first and only approved treatment for ataxia-telangiectasia (A-T) in the United States or anywhere in the world. This marks the second FDA-approved indication for AQNEURSA.
The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.
Casey Harrell, a 42-year-old man with ALS who lost his ability to speak, has successfully used a brain-computer interface for almost three years to communicate and control his computer, producing approximately 2 million words. The at-home brain implant represents a significant milestone in assistive technology for neurodegenerative disease patients.